Lisa Deschamps
Director/Board Member en VERONA PHARMA PLC .
Fortuna: 1 M $ al 31/03/2024
Perfil
Lisa Deschamps is currently the Chief Executive Officer & Executive Director at AviadoBio Ltd., an Independent Non-Executive Director at Verona Pharma Plc, and a Director at Reset Pharmaceuticals, Inc. Her former position was as the Chief Business Officer & Senior Vice President at Novartis Gene Therapies, Inc. from 2019 to 2021.
She received her undergraduate degree from Iona College in 1992 and her MBA from The Leonard N Stern School of Business in 2014.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
VERONA PHARMA PLC
0.12% | 28/04/2023 | 562 560 ( 0.12% ) | 1 M $ | 31/03/2024 |
Cargos activos de Lisa Deschamps
Empresas | Cargo | Inicio |
---|---|---|
VERONA PHARMA PLC | Director/Board Member | 01/03/2021 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Chief Executive Officer | 01/10/2021 |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Director/Board Member | - |
Antiguos cargos conocidos de Lisa Deschamps.
Empresas | Cargo | Fin |
---|---|---|
AVEXIS INC | Director/Board Member | 01/09/2019 |
Formación de Lisa Deschamps.
Iona College | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
VERONA PHARMA PLC | Health Technology |
Empresas privadas | 3 |
---|---|
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Health Technology |
- Bolsa de valores
- Insiders
- Lisa Deschamps